Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6PGO

Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor

6PGO の概要
エントリーDOI10.2210/pdb6pgo/pdb
分子名称GTPase KRas, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ... (5 entities in total)
機能のキーワードinhibitor, gtpase, signaling protein, signaling protein-inhibitor complex, signaling protein/inhibitor
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計43994.15
構造登録者
Mohr, C. (登録日: 2019-06-24, 公開日: 2019-12-25, 最終更新日: 2024-11-20)
主引用文献Lanman, B.A.,Allen, J.R.,Allen, J.G.,Amegadzie, A.K.,Ashton, K.S.,Booker, S.K.,Chen, J.J.,Chen, N.,Frohn, M.J.,Goodman, G.,Kopecky, D.J.,Liu, L.,Lopez, P.,Low, J.D.,Ma, V.,Minatti, A.E.,Nguyen, T.T.,Nishimura, N.,Pickrell, A.J.,Reed, A.B.,Shin, Y.,Siegmund, A.C.,Tamayo, N.A.,Tegley, C.M.,Walton, M.C.,Wang, H.L.,Wurz, R.P.,Xue, M.,Yang, K.C.,Achanta, P.,Bartberger, M.D.,Canon, J.,Hollis, L.S.,McCarter, J.D.,Mohr, C.,Rex, K.,Saiki, A.Y.,San Miguel, T.,Volak, L.P.,Wang, K.H.,Whittington, D.A.,Zech, S.G.,Lipford, J.R.,Cee, V.J.
Discovery of a Covalent Inhibitor of KRASG12C(AMG 510) for the Treatment of Solid Tumors.
J.Med.Chem., 63:52-65, 2020
Cited by
PubMed Abstract: KRAS has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRAS to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS inhibitor currently in phase I clinical trials (NCT03600883).
PubMed: 31820981
DOI: 10.1021/acs.jmedchem.9b01180
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.6 Å)
構造検証レポート
Validation report summary of 6pgo
検証レポート(詳細版)ダウンロードをダウンロード

237992

件を2025-06-25に公開中

PDB statisticsPDBj update infoContact PDBjnumon